On December 1, Shenzhen Mindray Biomedical Electronics Co., Ltd., a leading medical device company in China, announced that the acquisition of 75% of the shares of Diasys Diagnostic Systems GmbH (hereinafter referred to as "Diasys") in Germany was completed on November 30, with a transaction price of 11.5 billion euros.
Wu Hao, President of Mindray Medical, said, "Welcome Diasys to become a member of the Mindray familyThe completion of the acquisition of Diasys will enable us to quickly build Mindray's overseas first-chain platform, gain access to an excellent international talent team, and improve the supporting of in vitro diagnostic products. Mindray will provide resources to Diasys and leverage its international integration experience to quickly achieve synergistic development of both businesses. ”
We are honored to be a member of Mindray. We will empower each other to expand our global impact. Diasys is ready to work together to build the future. Diasys Founder DrGünther Gorka said.
According to the announcement, after the completion of the transaction, Mindray Netherlands, a wholly-owned subsidiary of Mindray Medical, has directly held 75% of the equity of Diasys, and enjoys various shareholder rights and assumes corresponding shareholder obligations in accordance with the law. Diasys and its subsidiaries will be included in the consolidated financial statements of Mindray.
The IVD business (i.e., "in vitro diagnostics business") is one of the three main business segments of Mindray Medical. According to the company's third quarter report for 2023, the company's operating income in the first three quarters was 2730.4 billion yuan, the revenue scale of in vitro diagnostic business accounts for more than one-third of the company's total revenue.
Build a global chain platform and deploy overseas and local
With this acquisition, Mindray aims to build the capacity building of a global ** chain platform for in vitro diagnostic products and accelerate the layout of overseas markets. According to the data, Diasys, founded in 1991, is a world-renowned in vitro diagnostic brand, and has been deeply engaged in the field of in vitro diagnostic reagents and quality control calibrators for more than 30 years. As the first brand in the world to launch stable, ready-to-use liquid biochemical reagents, Diasys products have a good reputation among customers around the world. Diasys is headquartered in Holzheim, Germany, and has production bases in Europe, Asia-Pacific, Latin America and other regions.
Mindray said that the acquisition of Diasys is an important step in the internationalization of the company's in vitro diagnostics business and is of great significance to the company. The IVD detection system consists of instruments and reagents, and in addition to product performance, customers also have high requirements for the timeliness of reagent delivery. Through this acquisition, Mindray will quickly gain access to the global first-chain platform to achieve localized production and delivery in major overseas markets, which can not only improve the delivery response to clients, but also enhance the comprehensive cost competitiveness of products, thereby supporting the eventual breakthrough of overseas medium and large sample size customer groups.
Improve the quality control and calibration package to improve the performance of the detection system
In 1991, Diasys was the first in the world to launch all-liquid, ready-to-use, long-term and stable biochemical reagents, and has a deep research and development experience in the field of biochemical reagents. In addition, Diasys also has good R&D and production capacity of quality controls and calibrators, which can provide customers with high-quality products.
According to Mindray, Diasys' quality control and calibrator capabilities can effectively complement the IVD product line. Quality control calibrators are an integral part of a complete inspection system and are important to improve the performance of the inspection system. At present, Mindray's IVD product line includes blood cell analysis, biochemical testing, immunoassays, coagulation testing, urinalysis and other subdivisions, and Diasys' quality control calibrator capabilities will effectively complement the existing IVD business system.
Mindray has extensive experience in cross-border mergers and acquisitions. Since 2008, the company has successively acquired DataScope in the United States, Zonare in the United States, ULCO in Australia and HyTest in Finland, all of which have achieved good integration results. After the completion of this transaction, Diasys will be integrated into Mindray's management system, and the integration teams of the two parties will work together and sincerely cooperate to promote the orderly development of Diasys integration work as planned through product empowerment, joint development, platform expansion, etc., so as to comprehensively enhance the comprehensive competitiveness of Mindray Medical's IVD business and serve the company's long-term development strategy.
Linghexun plus members, watch more exclusive content for free: 8 major financial columns, exclusive interpretation of the latest and hottest information dry goods, and grasp the market investment trend one step faster.